In a revealing disclosure, internal records have surfaced detailing a pivotal meeting between top officials from the Environmental Protection Agency (EPA) and Bayer’s CEO, Bill Anderson. This gathering took place on June 17, 2025, just months prior to significant actions taken by the Trump administration that appeared to bolster Bayer’s legal position regarding its glyphosate herbicide, notably Roundup. The discussions, centring on ongoing litigation linked to claims of cancer caused by glyphosate products, have raised serious concerns about the influence of corporate interests over public health regulations.
The High-Stakes Dialogue
The meeting, which also included other senior Bayer executives, was part of an ongoing effort by the German chemical giant to navigate through the mounting legal challenges it faces. Tens of thousands of individuals have filed lawsuits alleging that their cancers resulted from the use of Bayer’s glyphosate-based herbicides. Central to these claims is the assertion that Bayer failed to adequately inform consumers about the potential cancer risks associated with its products, a contention that has been supported by numerous scientific studies over the years.
Bayer’s strategy hinges on a legal argument that posits if the EPA does not mandate a cancer warning on its glyphosate products, the company cannot be held liable for omitting such warnings. While some courts have sided with Bayer on this preemption argument, others have decisively rejected it, including the Biden administration’s solicitor general. Conversely, the Trump administration has actively worked to advocate for Bayer’s position, demonstrating a marked shift in regulatory support.
A Pattern of Corporate Support
Bayer has characterised the June meeting as a standard aspect of the regulatory process, asserting that it has maintained transparency regarding its stance on glyphosate-related litigation. However, the timing and context of the discussions suggest a deeper intertwining of corporate and governmental interests. An internal email from the EPA, sent just days before the meeting, outlined that Bayer intended to raise “legal/judicial issues” and specifically mentioned “supreme court action” as a topic of discussion.
Since that meeting, the Trump administration has made several moves to support Bayer. Notably, on December 1, 2025, the solicitor general appointed by the Trump administration urged the Supreme Court to hear Bayer’s case, which the court subsequently agreed to do. Further actions included invoking the Defense Production Act to safeguard glyphosate production and submitting an amicus brief in support of Bayer, actions that have drawn significant criticism from various public health advocates.
Concerns Over Regulatory Integrity
The implications of such high-level meetings extend beyond corporate benefit; they raise troubling questions about the prioritisation of industry interests over public health. Nathan Donley, the environmental health science director for the Center for Biological Diversity, expressed alarm at the apparent prioritisation of pesticide manufacturers’ profits over the health and safety of the American populace. “When the CEO of one of the largest companies in the world is meeting with political appointees in a US regulatory office, it shows just how much power and influence these corporations have on decisions that can have very real consequences for the health of all Americans,” he noted.
Legal experts have echoed these sentiments, pointing out the troubling nature of private discussions that could significantly limit a company’s liability for health risks posed by its products. Whitney Di Bona, a consumer safety advocate, remarked, “We should also ask whether the agency gave the same chance to speak to the thousands of people who say they got cancer after using Roundup.”
This kind of access appears to favour corporate entities disproportionately, sidelining the voices of those most affected by the products in question. Naomi Oreskes, a Harvard professor, highlighted how such meetings reflect a broader pattern of industry influence that often eclipses the concerns of ordinary citizens.
Why it Matters
The revelations surrounding this meeting and the subsequent actions by the Trump administration highlight a critical intersection between corporate power and public health regulation. As Bayer continues to defend its glyphosate products amidst mounting litigation, the implications for consumer safety and regulatory integrity remain profound. This situation serves as a stark reminder of the need for vigilance in ensuring that regulatory bodies operate transparently and in the public interest, rather than succumbing to the pressures of powerful corporate interests. The health of countless individuals hangs in the balance.
